How do companies develop a strategy that is both low cost and differentiated without being squeezed in the middle? Describes how to Teva, Israel’s first and largest multinational company, its worldwide dominance in generic pharmaceuticals, an industry that has undergone significant change over the last 20 years reached. Examines their strategies to defend themselves against increasingly the two low-cost competition from India and other emerging markets as well as big pharmaceutical companies, the adoption … Read more »

How do companies develop a strategy that is both low cost and differentiated without being squeezed in the middle? Describes how to Teva, Israel’s first and largest multinational company, its worldwide dominance in generic pharmaceuticals, an industry that has undergone significant change over the last 20 years reached. Examines its strategies against the two low-cost competition from India and other emerging markets as well as Big Pharma companies adopting increasingly aggressive tactics to defend in genetics.
«Hide

from
Tarun Khanna,
Krishna G. Palepu,
Claudine Madras
Source: HBS Premier Case Collection
28 pages.
Publication Date: Sep 18, in 2006. Prod #: 707 441 PDF-ENG
Teva Pharmaceutical Industries, Ltd. HBR case solution

[related_post themes="flat"]